Infectious Diseases
GSK’s meningococcal groups A, B, C, W, and Y vaccine (Penmenvy) has been approved by the FDA for use in individuals aged 10 through 25 years. Read More ›
Officials with Bavarian Nordic A/S have announced that the FDA has approved their recombinant chikungunya vaccine (Vimkunya) for injection, the first virus-like particle single-dose chikungunya vaccine in the United States for persons aged ≥12 years. Read More ›
Officials with AbbVie have announced that the FDA has approved aztreonam and avibactam (Emblaveo; AbbVie), as the first and only fixed-dose, intravenous, monobactam/β-lactamase inhibitor combination antibiotic. Read More ›
USU researchers noted they used observational retrospective analysis, with longitudinal data from the National Healthcare Safety Network that included about 48 hospitals and researcher surveys for both inpatient and outpatient clinics to take a more comprehensive, system-wide look at ASPs, since most available data has been at the facility level, rather than the entire system. Read More ›
On October 29, 2024, the Centers for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization Practices (ACIP) made some recommendations that are going to change the way immunization schedules look for 2025, particularly as they relate to pneumococcal disease and COVID-19 Read More ›
The global COVID pandemic shed new light on much-needed areas in emerging infectious disease research, one of which was a need for larger and expanded areas of biorepositories. Read More ›
In October 2024, officials with the CDC dropped the initial age at which adults are recommended to get vaccinated against pneumococcal disease, from 65 to 50 years, Goad noted. Read More ›